Skip to main content

Advertisement

Table 2 Types and status of cancers in patients with neutropenic pneumonia

From: Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Variables β-lactam group (n = 72) Combination group (n = 93) P-value
Type of cancer
 Head and neck 3 (4.2%) 1 (1.1%) 0.319
 Lung 36 (50.0%) 38 (40.9%) 0.242
 Breast 7 (9.7%) 12 (12.9%) 0.526
 Esophageal and gastric 8 (11.1%) 6 (6.5%) 0.287
 Colorectal 1 (1.4%) 5 (5.4%) 0.233
 Hepatobiliary and pancreatic 0 (0.0%) 3 (3.2%) 0.258
 Bladder 1 (1.4%) 5 (5.4%) 0.233
 Prostate 0 (0.0%) 4 (4.3%) 0.133
 Melanoma and sarcoma 1 (1.4%) 5 (5.4%) 0.233
 Lymphoma and myeloma 15 (20.8%) 13 (14.0%) 0.245
Cancer status
 Curative setting 32 (44.4%) 35 (37.6%) 0.377
  Neoadjuvant and adjuvant 12 (16.7%) 20 (21.5%) 0.436
  Definitive 20 (27.8%) 15 (16.1%) 0.069
 Palliative settinga 40 (55.6%) 58 (62.4%) 0.377
  Complete response 1 (2.5%) 0 (0.0%) 0.436
  Partial response 2 (5.0%) 4 (6.9%) 0.697
  Stable disease 0 (0.0%) 4 (6.9%) 0.133
  Progressed or relapse 22 (55%) 31 (53.4%) 0.705
  Before evaluation 15 (37.5%) 19 (32.8%) 0.949
  1. Data are expressed as number (%) of patients
  2. aThe response to chemotherapy was evaluated according to the World Health Organization (WHO) criteria or Response Evaluation Criteria in Solid Tumors (RECIST) guidelines